Patents Assigned to Pharmacia & Upjohn Co.
  • Patent number: 7572924
    Abstract: The present invention relates to pyrrole substituted-2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: August 11, 2009
    Assignees: Sugen, Inc., Pharmacia & Upjohn Co.
    Inventors: Peng Cho Tang, Todd Anthony Miller, Xiaoyuan Li, Connie Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • Publication number: 20090075316
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: July 18, 2008
    Publication date: March 19, 2009
    Applicant: PHARMACIA & UPJOHN CO.
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Publication number: 20080171349
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: July 11, 2007
    Publication date: July 17, 2008
    Applicant: PHARMACIA & UPJOHN CO.
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 7144897
    Abstract: Disclosed are compounds of formula X, which are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising compounds of formula X and methods of preparing the compounds of formula X are also disclosed.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: December 5, 2006
    Assignees: Elan Oharmaceuticals, Inc., Pharmacia & Upjohn, Co.
    Inventors: John Freskos, David L. Brown, Yvette M. Fobian, Larry Fang, Arthur Glenn Romero, Varghese John
  • Patent number: 6951950
    Abstract: The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: October 4, 2005
    Assignee: Pharmacia & Upjohn Co
    Inventors: Ivan Michael Richards, Timothy Gordon Heath, Martin Durham Meglasson
  • Patent number: 6946486
    Abstract: The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: September 20, 2005
    Assignee: Pharmacia & Upjohn Co.
    Inventor: John Gregory Slatter
  • Patent number: 6916914
    Abstract: This invention discloses a commercially advantageous process for extraction and purification of protein from microorganisms. The initial steps of the process are useful for purifying many insoluble proteins while later steps are designed to renature denatured somatotropins produced by transformed microorganisms. The process is especially useful for purifying recombinantly-produced bovine somatotropin.
    Type: Grant
    Filed: June 13, 1986
    Date of Patent: July 12, 2005
    Assignee: Pharmacia & Upjohn Co.
    Inventors: Timothy W. Evans, Mark W. Knuth
  • Publication number: 20040127542
    Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: May 5, 2003
    Publication date: July 1, 2004
    Applicant: Pharmacia & Upjohn Co.
    Inventors: Malcolm Wilson Moon, Walter Morozowich, Ping Gao
  • Publication number: 20040063773
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: April 14, 2003
    Publication date: April 1, 2004
    Applicant: SUGEN, Inc. & Pharmacia & Upjohn Co.
    Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Thomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • Patent number: 6673793
    Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: January 6, 2004
    Assignee: Pharmacia & Upjohn Co.
    Inventors: Steven Ronald Turner, Suvit Thaisrivongs, Atli Thorarensen
  • Patent number: 6624160
    Abstract: This invention provides compounds of formula I; which are useful as antiviral agents.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: September 23, 2003
    Assignee: Pharmacia & Upjohn Co.
    Inventors: Valerie A. Vaillancourt, Scott D. Larsen, Sajiv K. Nair
  • Patent number: 6573293
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: June 3, 2003
    Assignees: Sugen, Inc., Pharmacia & Upjohn Co.
    Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • Patent number: 6395708
    Abstract: The present invention relates to a method for preventing irinotecan-induced or camptothecin-induced or camptothecin- analog-induced diarrhea by administering an effective amount of octreotide. In particular the invention concerns new methods, combination formulations and kits to prevent late diarrhea caused by irinotecan or camptothecin, or camptothecin-analog administration.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: May 28, 2002
    Assignees: Novartis, A.G., Pharmacia & Upjohn Co.
    Inventors: Langdon L. Miller, John David Rothermel, Hugh Michael O'Dowd
  • Patent number: 6387896
    Abstract: The present invention provides compounds of formula I useful as antimicrobial agents wherein W, X, Y, R1, R2 and n are as defined in thereof.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: May 14, 2002
    Assignee: Pharmacia & Upjohn Co.
    Inventors: Michael J. Genin, Michael Robert Barbachyn, Jackson B. Hester, Jr., Paul D. Johnson
  • Patent number: 6387900
    Abstract: 3-ureido-pyrazole derivatives represented by formula (I): where R, R1 and R2 are as described herein, or pharmnaceutically acceptable salts thereof; are useful, for example, for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: May 14, 2002
    Assignees: Pharmacia & Upjohn S.p.A., Pharmacia & Upjohn Co.
    Inventors: Paolo Pevarello, Paolo Orsini, Gabriella Traquandi, Mario Varasi, Edward L. Fritzen, Martha A. Warpehoski, Betsy S. Pierce
  • Patent number: 6218418
    Abstract: Compounds which are 3-amino-pyrazole derivatives represented by formula (I): where R is a C3-C6 cycloalkyl group, which may optionally be substituted by a straight or branched C1-C6 alkyl group, and R1 is a straight or branched C1-C6 alkyl group or a C2-C4 alkenyl, cycloalkyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl and arylalkenyl, which may be optionally substituted; or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: April 17, 2001
    Assignees: Pharmacia & Upjohn S.p.A, Pharmacia & Upjohn Co.
    Inventors: Paolo Pevarello, Paolo Orsini, Gabriella Traquandi, Mario Varasi, Edward L. Fritzen, Martha A. Warpehoski, Betsy S. Pierce, Maria Gabriella Brasca
  • Patent number: 6159935
    Abstract: The present invention relates to a method for preventing irinotecan-induced or camptothecin-induced or camptothecin-analog-induced diarrhea by administering an effective amount of octreotide. In particular the invention concerns new methods, combination formulations and kits to prevent late diarrhea caused by irinotecan or camptothecin, or camptothecin-analog administration.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: December 12, 2000
    Assignees: Pharmacia & UpJohn Co., Novartis, A.G.
    Inventors: Langdon L. Miller, John David Rothermel, Hugh Michael O'Dowd